Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease : A Randomized Clinical Trial

Leta, Valentina ; Zinzalias, Pavlos ; Batzu, Lucia ; Mandal, Gargi ; Staunton, Juliet ; Jernstedt, Frida ; Rosqvist, Kristina LU ; Timpka, Jonathan LU ; van Vliet, Trinette LU and Trivedi, Dhaval , et al. (2025) In Movement Disorders p.1-12
Abstract

Background: Gut dysbiosis and gut-brain-axis involvement in people with Parkinson's disease (PwP) support the use of gut-microbiota-modulating interventions. Probiotics may help manage constipation in PwP; however, mechanisms underpinning additional beneficial properties are unknown. Objective: The aim was evaluating the effects of a probiotic (Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Enterococcus faecium) on gut microbiota, inflammation, motor and non-motor symptoms (NMS) in PwP and constipation. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial (NCT05146921), PwP and constipation were randomized (1:1) to receive either the probiotic (4.08 × 108... (More)

Background: Gut dysbiosis and gut-brain-axis involvement in people with Parkinson's disease (PwP) support the use of gut-microbiota-modulating interventions. Probiotics may help manage constipation in PwP; however, mechanisms underpinning additional beneficial properties are unknown. Objective: The aim was evaluating the effects of a probiotic (Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Enterococcus faecium) on gut microbiota, inflammation, motor and non-motor symptoms (NMS) in PwP and constipation. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial (NCT05146921), PwP and constipation were randomized (1:1) to receive either the probiotic (4.08 × 108 CFU/mL) or placebo orally (70 mL/day) for 12 weeks. The primary endpoint was the differential abundance of gut microbiota taxa between baseline and end-of-treatment in the active versus placebo group. Secondary/exploratory endpoints included changes in inflammatory cytokines plasma levels, short-chain fatty acids (SCFAs) plasma and fecal levels, motor and NMS outcomes after 12 weeks. A per-protocol analysis was performed. Results: Between July 17, 2019 and February 6, 2022, 74 participants were randomized. Data from 35 (probiotic) and 33 (placebo) participants were analyzed. Enrichments of bacteria with beneficial health-related properties (Odoribacteraceae, Enterococcaceae, and Blautia faecicola) were observed in the active group compared to placebo (P ≤ 0.05). Proinflammatory cytokine TNF-α plasma levels decreased with probiotic treatment and increased with placebo (P < 0.05). No changes in SCFAs levels were observed. Reductions in time-to-on and NMS scale scores (P < 0.05) were observed only in the active group. Conclusions: This probiotic was effective in beneficially enriching the gut microbiota with potential to reduce systemic inflammation, shortening time-to-on following levodopa administration, and alleviating NMS burden in PwP experiencing constipation.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
gut microbiota, inflammation, motor symptoms, non-motor symptoms, Parkinson's disease, probiotics
in
Movement Disorders
pages
1 - 12
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:105019602427
ISSN
0885-3185
DOI
10.1002/mds.70047
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
id
804697d5-74e9-4ef8-8c19-30ef38e00de0
date added to LUP
2025-11-08 16:42:10
date last changed
2025-11-11 02:24:11
@article{804697d5-74e9-4ef8-8c19-30ef38e00de0,
  abstract     = {{<p>Background: Gut dysbiosis and gut-brain-axis involvement in people with Parkinson's disease (PwP) support the use of gut-microbiota-modulating interventions. Probiotics may help manage constipation in PwP; however, mechanisms underpinning additional beneficial properties are unknown. Objective: The aim was evaluating the effects of a probiotic (Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Enterococcus faecium) on gut microbiota, inflammation, motor and non-motor symptoms (NMS) in PwP and constipation. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial (NCT05146921), PwP and constipation were randomized (1:1) to receive either the probiotic (4.08 × 10<sup>8</sup> CFU/mL) or placebo orally (70 mL/day) for 12 weeks. The primary endpoint was the differential abundance of gut microbiota taxa between baseline and end-of-treatment in the active versus placebo group. Secondary/exploratory endpoints included changes in inflammatory cytokines plasma levels, short-chain fatty acids (SCFAs) plasma and fecal levels, motor and NMS outcomes after 12 weeks. A per-protocol analysis was performed. Results: Between July 17, 2019 and February 6, 2022, 74 participants were randomized. Data from 35 (probiotic) and 33 (placebo) participants were analyzed. Enrichments of bacteria with beneficial health-related properties (Odoribacteraceae, Enterococcaceae, and Blautia faecicola) were observed in the active group compared to placebo (P ≤ 0.05). Proinflammatory cytokine TNF-α plasma levels decreased with probiotic treatment and increased with placebo (P &lt; 0.05). No changes in SCFAs levels were observed. Reductions in time-to-on and NMS scale scores (P &lt; 0.05) were observed only in the active group. Conclusions: This probiotic was effective in beneficially enriching the gut microbiota with potential to reduce systemic inflammation, shortening time-to-on following levodopa administration, and alleviating NMS burden in PwP experiencing constipation.</p>}},
  author       = {{Leta, Valentina and Zinzalias, Pavlos and Batzu, Lucia and Mandal, Gargi and Staunton, Juliet and Jernstedt, Frida and Rosqvist, Kristina and Timpka, Jonathan and van Vliet, Trinette and Trivedi, Dhaval and Podlewska, Aleksandra and Parry, Miriam and van Wamelen, Daniel J. and Rizos, Alexandra and Sportelli, Carolina and Bonder, Ana Laura and Chung-Faye, Guy and Falup-Pecurariu, Cristian and Gaisford, Simon and Moretto, Edoardo and Le Gall, Gwenaelle and Vauzour, David and Rodriguez-Mateos, Ana and Sauerbier, Anna and Rodriguez Blazquez, Carmen and Ghyselinck, Jonas and Marsaux, Benoît and Pariante, Carmine Maria and Borsini, Alessandra and Odin, Per and Ray Chaudhuri, Kallol}},
  issn         = {{0885-3185}},
  keywords     = {{gut microbiota; inflammation; motor symptoms; non-motor symptoms; Parkinson's disease; probiotics}},
  language     = {{eng}},
  pages        = {{1--12}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Movement Disorders}},
  title        = {{Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease : A Randomized Clinical Trial}},
  url          = {{http://dx.doi.org/10.1002/mds.70047}},
  doi          = {{10.1002/mds.70047}},
  year         = {{2025}},
}